DNTHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Dianthus Therapeutics, Inc. /DE/
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$74.54+2.45 (+3.40%)
Close on Oct 19, 2026
- Market cap
- $4.18B
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Dianthus Therapeutics, Inc. /DE/ revenue by segment
By business segment
By product or service
By region
From the segment and revenue-disaggregation notes of Dianthus Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.